Dr. Lal Pathlabs, incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 15012.92 Crore) operating in Hospitals & A...

Promoters held 55.05 per cent stake in the company as of 30-Sep-2022, while FIIs owned 22.37 per cent, DIIs 6.27 per cent.

Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, ...

Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, ...

CLSA has retained buy rating on GAIL and sell rating on ONGC.

A total of 1,892 shares changed hands on the counter till 10:58AM (IST).

The company said it served 1.94 crore patients and processed 4.77 crore samples

A source said the AGM was "disrupted by supporters of general secretary Vinod Tihara after resolution 3, 4 and removal of its Ombudsman Jus...

Buy Dr. Lal Pathlabs Ltd. at a price target of Rs 1249.0 and a stoploss at Rs 1136 from entry point.

Buy Dr. Lal Pathlabs Ltd. at a price target of Rs 1235.0 and a stoploss at Rs 1148 from entry point.

CLSA has retained sell rating on Ashok Leyland with a target price of Rs 65.

The results were on the expected lines as Sharma has the backing of BJP with the IOA president Narinder Batra throwing in all his might.

The number of senior executives, working with the BSE 500 companies who earned more than Rs 1 crore, increased by 43 to 848 in FY17 from th...

Buy Dr. Lal Pathlabs at a price target of Rs 900. Time period given by analyst is a year when Dr. Lal Pathlabs price can reach defined targ...

In an interview with ET Now, Om Prakash Manchanda, Whole-time Director & CEO, Dr Lal Pathlabs Ltd, gives his views on the company's Q2 resu...

"The market is growing at 16% to 17%. Our own growth is likely to be sustainable as we expand to newer markets and grow further — both orga...